Murphy Pohlad Asset Management LLC Eli Lilly & CO Transaction History

Murphy Pohlad Asset Management LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 12, 2024	SELL	$592.2 - $792.28 $50,929 - $68,136	-86 Reduced 13.48%	552 $429,000
Q4 2023 Jan 19, 2024	BUY	$525.19 - $619.13 $27,309 - $32,194	52 Added 8.87%	638 $371,000
Q1 2023 Apr 17, 2023	SELL	$310.63 - $364.82 $62,126 - $72,964	-200 Reduced 25.45%	586 $201,000
Q4 2021 Feb 11, 2022	BUY	$224.85 - $279.04 $176,732 - $219,325	786 New	786 $217,000
Q2 2021 Aug 11, 2021	SELL	$180.55 - $233.54 $268,297 - $347,040	-1,486 Closed	0 $0
Q1 2020 May 13, 2020	BUY	$119.05 - $147.35 $176,908 - $218,962	1,486 New	1,486 $206,000
Q1 2019 May 07, 2019	SELL	$111.31 - $131.02 $198,799 - $234,001	-1,786 Closed	0 $0
Q4 2018 Feb 13, 2019	BUY	$105.9 - $118.64 $189,137 - $211,891	1,786 New	1,786 $206,000

4,004

752M

8.27M

10.5M

Ticker LLY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 950,174,976
Market Cap $711B
Description
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...

Get notified when there are updates to the investment portfolio of Murphy Pohlad Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Murphy Pohlad Asset Management LLC with notifications on news.